As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Michael A. Weber, MD

Professor of Medicine, State University of New York, Downstate College of Medicine, Brooklyn, New York

Disclosures

Disclosure: Michael A. Weber, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Daiichi Sankyo, Inc.; Forest Laboratories, Inc.; Medtronic, Inc.; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Daiichi Sankyo, Inc.; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.

Dr Weber does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Weber does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

David J. Cohen, MD

Missouri Endowed Professor of Cardiovascular Research, University of Missouri - Kansas City School of Medicine; Director of Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas City, Missouri

Disclosures

Disclosure: David J. Cohen, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Vascular; AstraZeneca Pharmaceuticals LP; Lilly; Medtronic, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Lilly
Received grants for clinical research from: Abbott Vascular; AstraZeneca Pharmaceuticals LP; Biomet, Inc.; Boston Scientific; Daiichi Sankyo, Inc.; Edwards Lifesciences; Lilly; Medtronic, Inc.

Dr Cohen does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Cohen does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Jan B. Pietzsch, PhD

President & CEO, Wing Tech Inc., Menlo Park, California; Consulting Associate Professor, Management Science & Engineering, Stanford University, Stanford, California

Disclosures

Disclosure: Jan B. Pietzsch, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic, Inc.

Dr Pietzsch does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Pietzsch does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

George Boutsalis, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME

Economic Implications of Uncontrolled Hypertension

Authors: Michael A. Weber, MD; David J. Cohen, MD; Jan B. Pietzsch, PhD
CME Released: 1/30/2014
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 1/30/2015, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, interventional cardiologists, and nephrologists.

The goal of this activity is to highlight the costs associated with uncontrolled hypertension and cost-effective strategies to manage patients with this condition.

Upon completion of this activity, participants will be able to:

Review the economic and clinical costs associated with uncontrolled hypertension.
Assess the cost-effectiveness of renal denervation to improve the clinical management of patients with uncontrolled hypertension.

Disclosures

Author(s)

Michael A. Weber, MD

Professor of Medicine, State University of New York, Downstate College of Medicine, Brooklyn, New York

Disclosures

Disclosure: Michael A. Weber, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Daiichi Sankyo, Inc.; Forest Laboratories, Inc.; Medtronic, Inc.; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Daiichi Sankyo, Inc.; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.

Dr Weber does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Weber does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

David J. Cohen, MD

Missouri Endowed Professor of Cardiovascular Research, University of Missouri - Kansas City School of Medicine; Director of Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas City, Missouri

Disclosures

Disclosure: David J. Cohen, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Vascular; AstraZeneca Pharmaceuticals LP; Lilly; Medtronic, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Lilly
Received grants for clinical research from: Abbott Vascular; AstraZeneca Pharmaceuticals LP; Biomet, Inc.; Boston Scientific; Daiichi Sankyo, Inc.; Edwards Lifesciences; Lilly; Medtronic, Inc.

Dr Cohen does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Cohen does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Jan B. Pietzsch, PhD

President & CEO, Wing Tech Inc., Menlo Park, California; Consulting Associate Professor, Management Science & Engineering, Stanford University, Stanford, California

Disclosures

Disclosure: Jan B. Pietzsch, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic, Inc.

Dr Pietzsch does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Pietzsch does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

George Boutsalis, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME

Economic Implications of Uncontrolled Hypertension

Authors: Michael A. Weber, MD; David J. Cohen, MD; Jan B. Pietzsch, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 1/30/2014

Valid for credit through: 1/30/2015, 11:59 PM EST

processing....

This feature requires the newest version of Flash. You can download it here.

CME Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Author(s)

Michael A. Weber, MD

David J. Cohen, MD

Jan B. Pietzsch, PhD

Editor(s)

George Boutsalis, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

Peer Reviewer

CME

Economic Implications of Uncontrolled Hypertension

Target Audience and Goal Statement

Disclosures

Author(s)

Michael A. Weber, MD

David J. Cohen, MD

Jan B. Pietzsch, PhD

Editor(s)

George Boutsalis, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Economic Implications of Uncontrolled Hypertension